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Aim: To investigate whether apoM is excreted in urine of children undergoing heart 
surgery and the potential of apoM as early biomarker of acute kidney injury (AKI). 
Materials & methods: Urine was collected in children undergoing heart surgery. 
ApoM was measured with ELISA. U-apoM was characterized by gel filtration 
chromatography and western blotting. Results: ApoM was excreted into the urine 
0–4 h postoperatively as the full-length apoM in particles smaller than plasma HDL. At 
0 h, U-apoM predicted AKI with an area under the receiver-operating characteristics 
curve of 0.70 (p < 0.018). Sensitivity was 0.71 and specificity was 0.68 at a cutoff level 
at 1.45 nmol/l. Conclusion: ApoM is excreted in the urine of children after cardiac 
surgery. Its potential as biomarker of AKI deserves exploration.
Keywords:  acute kidney injury • AKI • apoM • Apolipoprotein M • biomarker • cardiac 
surgery • urine
Apolipoprotein M (apoM) is a lipocalin dis-
covered in 1999 [1,2]. ApoM exerts antiathero-
genic and anti-inflammatory effects [3–6] and 
has recently been identified as plasma carrier 
of sphingosine-1-phosphate (S1P) [7]. The 
apoM gene is expressed in the liver and in 
the kidney proximal tubular epithelium [1,8]. 
The ApoM protein has an unusual feature of 
a retained hydrophobic signal peptide which 
attaches it to HDL [9,10]. The signal peptide 
sequence likely makes free apoM insoluble 
in water. Hence, there is no ‘free’ apoM in 
plasma [1,10]. The large size of HDL (∼150–
400 kDa [11]) prevents glomerular filtration 
and loss of plasma apoM in urine.
Little is known about the biological func-
tion of apoM in the kidney. Megalin is a 
receptor for apoM and likely contributes to 
the reuptake of apoM from preurine at the 
luminal side of the kidney proximal tubule 
cells [12]. Hence, there is no apoM in the 
urine under normal circumstances [12]. In 
contrast, apoM has been shown in robust 
amounts in the urine of megalin knockout 
mice [12]. These previous results suggest that 
apoM both undergoes secretion and megalin-
mediated reuptake in the kidney proximal 
tubule epithelium.
Damage to the kidney proximal tubular 
epithelium takes part in the pathophysiology 
of acute kidney injury (AKI). AKI is associ-
ated with increased risk of death in hospital-
ized patients [13] and is a known complication 
to cardiac surgery [14]. In adults, reported 
incidences of postoperative AKI are highest 
in patients with preoperative risk factors such 
as nephrotoxic medication, insulin-depen-
dent diabetes, peripheral, vascular disease 
and lung disease [15]. A strong intraoperative 
risk factor of AKI is cardiopulmonary bypass 
(CPB) [15]. The risk of AKI increases with 
longer extra corporeal circulation time [15]. 
The use of CPB introduces an inflammatory 
state, which can cause kidney injury. Other 
factors related to CPB are hemodilution, 
nonpulsatile flow and possible embolism dur-
ing aortic cannulation and clamping that can 
cause ischemic renal damage [15].
CPB is often indispensable in surgical 
correction of congenital heart disease in 
children. Accordingly, children undergoing 
cardiac surgery are in great risk of AKI and 
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reports have shown 28–64% incidence of postopera-
tive AKI [16–20]. The diagnosis of AKI following the 
RIFLE (Risk, Injury, Failure, Loss, End stage) [21], 
AKIN (Acute Kidney Injury Network) [22] or pRIFLE 
(modified pediatric RIFLE) criteria [23] is not possible 
until 1–3 days after the kidney insult with the currently 
used markers of glomerular filtration (P-creatinine, 
estimated glomerular filtration (eGFR) or urinary out-
put). Biomarkers for AKI, which reflect kidney injury 
rather than glomerular filtration, may reduce the time 
before diagnosis to hours [24]. This could allow earlier 
intervention and possibly limit the kidney damage and 
decrease the mortality of postcardiac surgery AKI. 
Already, many biomarkers have emerged. With vary-
ing sensitivity and specificity in different clinical set-
tings they reflect different parts of the AKI pathology 
depending on patient population and kidney insult. 
A panel of biomarkers for AKI to cover the span of 
the AKI pathology is therefore a probable future sce-
nario, and is why investigation of further biomarkers 
is  relevant.
Disruption of the secretion and reuptake cycle of 
apoM in the kidney by damage to the proximal tubular 
cells, particularly in AKI, may result in loss of apoM in 
the urine. We chose to investigate the AKI biomarker 
potential of U-apoM to test this idea. We speculated 
that U-apoM possibly could be more specific than 
NGAL, since U-apoM is not detectable in urine of 
healthy subjects and would only originate from the 
kidney, due to the tight apoM-HDL association in 
plasma.
The aims of the present study were to examine 
the stability of apoM in urine and whether apoM is 
excreted in the urine of children undergoing heart sur-
gery. Second, to test the ability of U-apoM in predict-
ing AKI and compare it to NGAL. Third, to do molec-
ular characterization of U-apoM and to investigate 
the pathophysiology of apoM secretion by measuring 




Fifty children (median age: 0.5 years [0.01–14.9 
years]) undergoing operation for congenital heart mal-
formation were prospectively recruited from Novem-
ber 2009 to January 2011 at Rigshospitalet, Copen-
hagen, Denmark. With no prior reports of human 
U-apoM secretion, lack of expected U-apoM levels 
precluded power calculations. Instead, a sample size of 
N = 50 was chosen to obtain N ≥ 10 of patients with 
AKI, by assuming minimum 20% incidence of AKI 
in our patient cohort. Exclusion criteria were diabe-
tes mellitus, chronic kidney disease, incorrect sample 
handling or pre- or per-operative use of medication 
with a reported incidence of nephrotoxic side effects 
of >1%. Two patients were excluded from analyses due 
to wrong sample handling and preoperative treatment 
with gentamicin, respectively. One patient without 
AKI (no. 35) was excluded from statistical analyses 
due to an outlier apoM-concentration. Patient flow is 
described in Figure 1. The study is reported according 
to the STROBE recommendations.
Patients were monitored with P-creatinine and 
diuresis as part of the standard procedure after sur-
gery. AKI was defined according to the newly recom-
mended KDIGO staging of AKI, which incorporates 
the RIFLE, pRIFLE and AKIN criteria [25]. Twenty-
two of 48 patients developed AKI. AKI diagnoses were 
based on a >1.5-fold increase or >26.5 μM increase in 
P-creatinine or eGFR <35 ml/min per 1.73 m2. None 
of the patients met the criteria for oliguria/anuria in 
AKI.
Before enrollment, informed written consent was 
obtained from parents or legal guardians of the chil-
dren. The study was approved by the Danish Ethics 
Committee for Region Hovedstaden (H-D-2008-
049) and registered with The Danish Data Protection 
Agency (2008-41-2222).
Eight adult patients with nondiabetic nephropathy 
enrolled in a multicenter trial by the Holland Nephrol-
ogy Study (HONEST) Group were included to study 
apoM in the urine of patients with severe protein-
uria without AKI. At time of inclusion, all patients 
had blood pressure >125/75 mmHg and protein-
uria >1.0 g/day despite treatment with maximal dose 
of ACE inhibitors. The study is registered with the 
 Netherlands Trial Register (NTR675) [26].
Patient data
For the children in this study, P-creatinine was obtained 
from the patient electronic biochemical charts. Age, 
weight, height, sex, extra corporeal circulation time, 
operation time and aortic clamp time were noted from 
the patients’ anesthetic and cardio-pulmonary perfu-
sion charts. Diagnosis, intervention procedure and 
number of prior operations were obtained from the 
surgical procedure registry database ‘PATS’. Length of 
stay in the intensive care unit was extracted from Intel-
liVue Clinical Information Portfolio (ICIP, Phillips). 
Diuresis was noted from the anesthetic charts and 
drawn from ICIP. Medication prior to and during the 
study period was obtained from the electronic patient 
medication charts ‘EPM’.
Urine sampling
A baseline urine sample was taken from the children 
preoperatively at the time of bladder catheter insertion. 
www.futuremedicine.com 83
Figure 1. Patient flow.
Recruited 
n = 50
Not included (n = 116) due to:
    •    Lack of time for parents to consider 
         participation (emergency operation) 
    •    Refused to participate 
    •    >14 years old
    •    Project coordinator not present
Excluded after recruitment (n = 2):
    •    Gentamicin administered pre-operatively
    •    Wrong sample handling
Data available for analysis
n = 47
Non-AKI patient excluded due to outlier apoM 
concentration (n = 1)
Children undergoing heart surgery at Rigshospitalet, 
Copenhagen, Denmark 
Nov 2009–Jan 2011
Samples available for analysis 
n = 48
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Collection of postoperative urine was initiated at time 
0, in other words, the time of closure of the sternum, 
and was performed every 2 h for the first 12 h and at 24 
h. In two cases, the sternum was not sutured immedi-
ately after the operation due to bleeding. The sampling 
of urine was instead initiated at the time of transfer 
to the intensive care unit. All postoperative urine sam-
pling was done from the collecting bag, which was 
emptied at all sampling time points. Urine was stored 
at 4°C for up to 48 h before centrifugation at 2000 
× g for 10 min. Supernatants were isolated and subse-
quently stored at -80°C.
Baseline 24-h urine samples were collected by the 
adult, proteinuric patients before the interventions of 
the multicenter trial started. Samples were stored at 
-80°C [26].
Plasma & urinary biochemistry
Plasma (P-) and urinary (U-) creatinine in children 
was measured with an enzymatic method on the Mod-
ular P Hitachi Automatic Analyzer (Roche, Hvidovre, 
Denmark). Urinary hemoglobin was measured on Uni-
cam UV2 UV/Vis Spectrophotometer (ATI Unicam, 
Cambridge, UK). U-protein and U-creatinine concen-
trations in proteinuric patients were measured with a 
turbidimetric assay using benzethonium chloride and 
an automated multianalyser, respectively (Modular, 
Roche Diagnostics, Mannheim, Germany) [26].
ApoM in urine was measured with enzyme-linked 
immunosorbent assay (ELISA) using the two mono-
clonal antibodies M58 and M42 described ear-
lier [4,27]. Interference of urine with the apoM mea-
surements was estimated by measuring the recovery 
of human apoM in plasma diluted with a buffer con-
taining 0, 10, 25 or 50% urine from a healthy indi-
vidual. The stability of apoM in urine was examined 
by adding plasma to urine (1 μl plasma per 100 μl 
urine). The mixture was left at room temperature 
or at 4°C for 0–5 days before examination of apoM 
by western blotting. ApoM in all urine samples was 
initially measured in a 1:10 dilution and repeated at 
higher  dilutions if necessary.
Urinary NGAL was measured with a sandwich 
ELISA using two monoclonal antibodies according 
to the manufacturer’s instructions (KIT 036, Bio-
Porto, Gentofte, Denmark). Results were converted 
into molar concentrations using a molecular weight of 
22,664 g/mol calculated from the amino acid sequence 
of NGAL at [28]. Urinary apoA1 measurements were 
done in 1:10 dilutions with a sandwich ELISA using a 
polyclonal capture antibody against ApoA1 (Q0496; 
DAKO, Glostrup, Denmark) and a monoclonal detec-
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tion antibody (M25, developed in B. Dahlbäck’s lab-
oratory) [29]. Potential interference of urine was esti-
mated as for the apoM ELISA with the recovery of 
plasma in a dilution buffer with 10% urine.
Gel filtration
Prior to gel filtration, urine (5 ml) was reduced in a 
vacuum centrifuge at 30°C (Eppendorf Concentrator 
5301, Hoersholm, Denmark), passed through a sterile 
filter (0.45 μm Millex filters, Millipore, MA, USA). 
The volume was adjusted with H
2
O to achieve a sev-
enfold concentration. Concentrated urine (400 μl) was 
loaded on to a Superose 6 or serially connected Supe-
rose 6 and 12 10/300 GL fast protein liquid columns 
(GE Healthcare Bio-Sciences, HillerØd, Denmark). 
Elution was done with phosphate buffered saline with 
EDTA (0.1 g/l) at a flow rate of 0.2 ml/min. Aliquots 
of 70 μl from single fractions and pools containing 
50 or 100 μl from each of respectively 5 or 7 adjacent 
fractions were concentrated in a vacuum centrifuge. 
With H
2
O volume adjustments to get loadable sam-
ple viscosity, the single fractions were fivefold and the 
Table 1. Characteristics and clinical outcomes of children developing AKI or no AKI.
 AKI* (n = 22) No AKI (n = 26) p-value
Characteristics    
Gender (% girls) 27% 54% 0.0825
Age (years) 5.7 (0.2–15) 8.5 (0.3–166) 0.0897
Patients with previous heart surgery (%) 9% 19% 0.429
Body surface area (m2) 0.31 (0.18–0.42) 0.38 (0.19–1.72) 0.1366
Clinical outcomes    
Surgery time (min) 222.5 (160–625) 175 (65–385) 0.0014
Extra corporeal circulation time (min) 128.5 (88–295) 85 (0–149) <0.0001
Aortic clamp time (min) 84.77 ± 6.98 44.46 ± 6.01 <0.0001
Fold change in p-creatinine** 2.0 (1.5–3.9) 1.1 (0.8–1.4) <0.0001
Time in the ICU (days) 3.6 (1–50) 1.1 (1–6) 0.0022
Diagnoses    
Aortic stenosis 0 1  
Aortopulmonary window 1 0  
Atrial septal defect 0 2  
Atrioventricular septal defect 0 3  
Coarctation of the aorta 1 1  
Coarctation of the aorta + ventricular septal defect 1 0  
Heart tumor 0 1  
Hypoplastic left heart syndrome 1 1  
Mitral insufficiency 1 1  
Partial anomalous pulmonary venous drainage 1 1  
Patent ductus arteriosus 0 1  
Tetralogy of Fallot 9 2  
Tetralogy of Fallot + major aortopulmonary collateral 
arteries
1 0  
Transposition of the great arteries 1 1  
Tricuspid atresia 0 1  
Truncus arteriosus 0 1  
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pools 17–28-fold concentrated before polyacrylamide 
 electrophoresis and western blot against apoM.
Western blotting
Aliquots of sterile filtered urine and concentrated sin-
gle or pooled gel filtration fractions were denatured 
and reduced prior to electrophoresis in 12% polyacryl-
amide gels (NuPAGE BisTris Mini Gel, Invitrogen). 
Upon transfer to a polyvinylidene fluoride membrane, 
apoM western blotting was performed with one of 
two rabbit polyclonal antibodies against human apoM 
(either EPR2904, from Genetex, CA, USA or an in-
house antibody from B. Dahlbäck’s laboratory) [4] or a 
mouse monoclonal antihuman apoM antibody (M58 
from B. Dahlbäck’s laboratory) [4]. For the ApoA1 
western blots, the polyvinylidene fluoride membranes 
were stripped with 0.4 M NaOH for 15 min followed 
by five washes (in 10 mM Tris, 0.1M NaCl, 0.25% 
Tween 20) for a total of 30 min. Subsequent western 
blotting was done using a rabbit polyclonal antihuman 
apoA1 antibody (Q0496, DAKO, Glostrup, Den-
mark). The secondary antibodies were goat antirab-
bit or goat antimouse polyclonal antibodies linked to 
horse radish peroxidase (p0448, DAKO, Glostrup, 
Denmark and M15345, BD Biosciences, Albertslund, 
Denmark).
Statistics
Data were analyzed in GraphPad Prism (CA, USA) 
using Spearman correlation, nonparametric Mann–
Whitney, unpaired t, and Fischer’s exact tests as indi-
cated. p < 0.05 was considered statistically significant.
We used the statistical software package Stata (ver-
sion 12.0; STATA Corp., College Station, TX, USA) 
to evaluate the biomarker potential of apoM. The 
predictive probability for AKI was calculated as the 
area under the receiver-operating characteristics (AU-
ROC) curve. We tested whether the AU-ROC curves 
for NGAL and apoM were equally good and evaluated 
whether the predicted probability from a logistic model 
including both urinary NGAL and urinary apoM dif-
fered significantly from a logistic model including 
 urinary NGAL alone.
Results
Patients
Twenty-two of 48 children developed postoperative 
AKI. The children with AKI compared with the non-
AKI group were not different with regards to age, gen-
der, number of previous heart surgery and body surface 
area. The children with AKI had longer surgery time, 
longer extra corporeal circulation time, longer aortic 
clamp time, and spent more postoperative time in the 
intensive care unit. Tetralogy of Fallot was associated 
with a significantly increased risk of AKI (Fisher’s 
exact test, p = 0.0059) (Table 1).
The basic characteristics of adult patients with 
 proteinuria are shown in Table 2.
Urinary apoM ELISA
There was no degradation of apoM in urine for up to 
5 days as judged by western blotting (Figure 2A). The 
putative interference of urine on apoM ELISA mea-
surements was studied by adding exogenous apoM 
to urine. The recovery of apoM in urine diluted 1:2, 
1:4 and 1:10 with ELISA dilution buffer was 86% 
(95% CI: 72–99%), 84% (95% CI: 75–92%) and 
79% (95% CI: 70–87%), respectively (Figure 2B). 
The detection limit of the urine apoM ELISA assay 
was 0.87 nmol/l as defined by the concentration of 
the lowest standard in the calibration curve. The coef-
ficient of variation was 11%. These results indicated 
that apoM could be measured in urine with the apoM 
ELISA employed.
Urinary ApoM excretion is temporarily induced 
after cardiac surgery in children
Urinary apoM was measured prior to and every 2 h after 
surgery. In accordance with the absence of apoM in the 
urine of normal mice, rats and humans in western blot-
ting analyses [12], the baseline concentration was less 
than the detection limit of the apoM ELISA (Figure 3). 
Notably, there was a pronounced temporary increase in 
the urinary apoM concentration from 0 to 4 h postop-
eratively in 40 of 48 children to a mean peak concentra-
tion of approximately 3 nmol/l (Figure 3A). The urinary 
apoM excretion had returned to baseline values 24 h 
after the operation in 46 of the children (Figure 3).
AKI was associated with an increased concentra-
tion of apoM in the urine at t = 0 h postoperatively 
(Figure 3A). When the apoM concentration was nor-
malized with U-creatinine, the difference between 
AKI and non-AKI children became even more appar-
ent (Figure 3B). Notably, there was no statistically sig-
nificant difference in the U-creatinine concentrations 
between the AKI and non-AKI children (data not 
shown).
Since the peak concentration of apoM in urine was 
only approximately 1/300 of the mean plasma apoM 
concentration (i.e., ∼0.9 μmol/l in adults [27]), we 
wondered whether the urinary apoM could be derived 
from blood contamination during the bladder cath-
eterization procedure. Therefore, we re-examined the 
U-apoM after excluding 12 children with biochemi-
cally detectable hemoglobinuria associated with the 
peak U-apoM concentration (Figure 3C & D). Even 
though the U-apoM concentration was slightly lower 
after excluding patients with hemoglobinuria, there 
86 Biomark. Med. (2016) 10(1)
Figure 2. (A) Stability of apoM in urine. Urine samples containing 1% plasma were stored at room temperature (RT) or 4°C for 0–5 
days. Subsequently, SDS-page gel electrophoresis was performed applying 16 μl of sample per well and 0.5 μl of plasma as positive 
control. Western blotting was done using a polyclonal antibody against apoM. (B) Recovery of apoM in urine was measured in 
duplicates in seven different dilutions of plasma corresponding to the dilutions of the standard curve. The dilution buffer contained 
50, 25 or 10% urine. (C) Standard curve of the apoM ELISA. A sandwich ELISA using two monoclonal antibodies (M58 and M42) and a 
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was still a higher U-apoM in the AKI than in the non-
AKI group when the U-apoM was normalized with 
U-creatinine (Figure 3D).
U-apoM correlates with U-NGAL
As for apoM, the urinary excretion of NGAL was 
essentially absent at baseline, increased temporarily at 
0–4 h after surgery, and was increased in the AKI com-
pared with the non-AKI group irrespectively of exclud-
ing children with hemoglobinuria (Figure 4A–D). The 
similarity of the excretion pattern of the two urinary 
proteins was in accordance with a close positive cor-
relation between U-apoM and U-NGAL (Spearman’s 
r = 0.8052, p < 0.0001, Figure 4E).
The ability of urinary NGAL to predict AKI at 0 h 
was significant with an area under the ROC curve of 
0.85 (SE 0.056; p < 0.0001; Figure 5B). Sensitivity was 
0.90 and specificity was 0.72 for a cutoff level at 0.48 
nmol/l (Table 3). ApoM was also a significant predictor 
of AKI at 0 h. The area under the ROC curve was 0.70 
(SE 0.079; p < 0.01779; Figure 5A). Sensitivity was 
0.71 and specificity 0.68 when cutoff was 1.45 nmol/l 
(Table 3). U-NGAL was better at predicting AKI than 
U-apoM (p < 0.0187). To test if U-apoM would add 
to the predictive value of U-NGAL, we compared 
the area under the ROC curve at 0 h between NGAL 
and NGAL adjusted for apoM. However, apoM did 
not increase the predictive ability of NGAL (data not 
shown).
Proteinuria is not accompanied by urinary 
excretion of apoM
To assess whether apoM excretion in the urine also 
occurs in patients with an impaired glomerular filtra-
tion barrier, we measured U-apoM in adult patients 
with severe proteinuria in the setting of nondiabetic 
nephropathy and found levels that were on aver-
age similar to the baseline values in children prior to 
heart surgery (Figure 6A). U-NGAL in the proteinuric 
patients was also low and at the level of the children’s 
baseline values (Figure 6B).
Urinary apoM in AKI is not associated with HDL
We characterized apoM in the urine to determine 
whether the U-apoM excretion in children originates 
from the plasma or is derived from the kidney. In 
plasma, apoM associates with large apoA1-containing 
HDL particles. The ratio between the measured con-
centrations of apoA1 in urine and the normal ApoA1 
plasma concentration was 1:10,000–1:100,000, that is, 
much lower than that for apoM (∼1:300). There was 
Table 2. Characteristics of adult proteinuric 
patients.
Gender (% women) 12.5
Age (years) 43.9 ± 5.5
Proteinuria (g/day) 1.0 ± 0.2
Creatinine clearance (ml/min) 72.8 ± 16.6
Systolic blood pressure (mmHg) 126 ± 4.8
Diastolic blood pressure (mmHg) 70 ± 4.4
Diagnoses  







Figure 3. Urinary apoM and urinary apoM/creatinine ratio in children undergoing cardiac surgery. A baseline 
urine sample was taken before the operation, and postoperative sampling was done every 2 h for the first 12 
h and then at 24 h. Patients were assigned to two groups – acute kidney injury (AKI) or no kidney affection 
(non-AKI) according to the KDIGO classification of AKI. An outlier (patient no. 35) has been omitted. Patients 
with hemoglobinuria were excluded in C + D. Points represent mean ± SEM. (A) U-apoM (nmol/l), *p = 0.0175. 
(B) U-apoM/U-creatinine ratio (nmol/mmol), *p = 0.0084, **p = 0.0345. (C) U-apoM (nmol/l). (D) U-apoM/U-



















































































































AKI, n = 15
Non-AKI, n = 20
AKI, n = 22
Non-AKI, n = 25
AKI, n = 15
Non-AKI, n = 20
AKI, n = 22
Non-AKI, n = 25
future science group
Urinary apoM in children undergoing heart surgery    Research Article
no significant difference in U-apoA1 levels between 
AKI versus non-AKI or proteinuria (Figure 6C), and, 
moreover, U-apoA1 did not correlate with U-NGAL 
or U-apoM and (data not shown).
To further characterize U-apoM, we performed 
gel filtration chromatography of urine from children 
with AKI (Figure 7A & B). The apparent size of plasma 
HDL is approximately 160–410 kDa [11]. As opposed 
to plasma apoM, U-apoM co-eluted with smaller 
particles (14–44 kDa) than HDL (Figure 7B). Upon 
delipidation and SDS-PAGE, the size of urinary apoM 
protein was approximately 25 kDa, which is similar to 
that of the plasma apoM protein, indicating that apoM 
is predominantly excreted from the kidney as the gly-
cosylated full length protein [1]. ApoA1 western blots 
revealed U-apoA1 in larger particles than U-apoM. 
This implies that the sparse amounts of apoA1 in urine 
are mainly associated with other particles than apoM 
(Figure 7A).
Discussion
This study demonstrates that apoM is excreted into the 
urine after cardiac surgery in children at 0–4 h postop-
eratively. The excretion peaks at 2 h. Forty-six percent 
of the children developed AKI. They had significantly 
higher U-apoM at the time of closure of sternum (t 
= 0) compared with the non-AKI patients. Increased 
U-apoM/creatinine ratio predicted AKI at 0 and 2 h 
postoperatively. The higher U-apoM/creatinine ratio 
in the AKI group was not a result of decreased glomer-
ular filtration and thereby lower U-creatinine. U-creat-
inine decreased from baseline until 2 h postoperatively 
in both groups, and there was no significant difference 
between the AKI and the non-AKI group.
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Figure 4. Urinary NGAL and urinary NGAL/creatinine ratio in children undergoing cardiac surgery. A baseline 
urine sample was taken before the operation, and postoperative sampling was done every 2 h for the first 12 h 
and then at 24 h. Patients were assigned to two groups – acute kidney injury (AKI) or no kidney affection (non-
AKI) according to the KDIGO classification of AKI. An outlier (patient no. 35) has been omitted. Patients with 
hemoglobinuria were excluded in C + D. Points represent mean ± SEM. (A) U-NGAL (nmol/l), *p < 0.0001, **p = 
0.0059. (B) U-NGAL/U-creatinine ratio (nmol/mmol), *p = 0.0005, **p = 0.0052. (C) U-NGAL (nmol/l), *p = 0.0009, 
**p = 0.0048. (D) U-NGAL/U-creatinine ratio (nmol/mmol), *p = 0.0027. **p = 0.0059. (E) Correlation between 2 
h U-apoM and U-NGAL measurements. Spearman r = 0.8052 (p < 0.0001). Pt no. 35 has been omitted from the 
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NGAL is a promising biomarker of AKI. It has 
been suggested that a multimarker approach with 
several biomarkers including NGAL may eventu-
ally allow rapid biochemical diagnosis of AKI [30]. 
NGAL is synthesized by myeloid cells in the bone 
marrow [31] and stored in the specific granules of 
neutrophils [32], but is also expressed in other tissues 
including kidney proximal tubule epithelium [33,34]. 
NGAL has bacteriostatic effects by binding of bac-
terial ferric siderophores and depleting bacteria of 
iron [35]. Furthermore, protective effects of NGAL in 
the kidney have been demonstrated with intravenous 
administration of NGAL in ischemia-reperfusion 
mouse models [36,37]. NGAL expression in the kidney 
is upregulated after ischemia [38] and U-NGAL has 
been proposed as an early biomarker of AKI [39,40]. 
Interpretation of U-NGAL can, however, be com-
plicated [41]. NGAL is mainly secreted as a 25 kDa 
monomer from the kidney proximal tubule cells. 
However, other molecular forms of NGAL originat-
ing from blood neutrophils and without relation to 
AKI can also be found in the urine [41,42]. Therefore, a 
higher specificity of U-apoM than U-NGAL for AKI 
could be speculated in clinical settings where P- and 
U-NGAL levels are elevated due to other reasons than 
AKI.
We compared U-apoM with U-NGAL to further 
examine the potential of apoM to diagnose AKI in 
children undergoing heart surgery. U-NGAL and 
U-apoM measurements were highly correlated, sug-
gesting that the pathophysiology causing apoM and 
NGAL secretion is interconnected in the present group 
of patients. Accordingly, we could not see a beneficial 
effect of measuring both U-NGAL and U-apoM in the 
prediction of AKI.
The fact, that U-NGAL was better than apoM in 
predicting AKI, is possibly dominated by two rea-
sons. First, U-NGAL baseline levels were low mean-
ing the measured increase in NGAL excretion was a 
specific effect of cardiac surgery. Second, the U-apoM 
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levels probably had two sources: ApoM from the 
kidney, reflecting tubular damage, and apoM from 
plasma due to hematuria. The U-apoM concentration 
being approximately 1/300 of that in plasma can be 
highly affected by plasma ‘contamination.’ Some chil-
dren had macroscopic hematuria. When omitting the 
children (25% of the study population) who had bio-
chemically detectable U-hemoglobin, the U-apoM/
creatinine remained significantly elevated in the AKI 
group at 2 and 2 h. A reduction of statistical power 
Table 3. ApoM and NGAL test characteristics.
 Sampling time 
(postoperative)
AUC p-value Cutoff (nmol/l) Sensitivity Specificity Likelihood ratio
U-apoM 0 h 0.7048 0.01779 1.45 0.71 0.68 2.23
    1.88 0.62 0.80 3.1
    2.65 0.48 0.84 2.98
    4.02 0.33 0.88 2.78
    4.83 0.29 0.92 3.57
    5.36 0.19 0.96 4.76
U-apoM 2 h 0.6544 0.09555 1.45 0.71 0.63 1.88
    1.86 0.59 0.67 1.76
    2.17 0.53 0.71 1.82
    2.95 0.47 0.75 1.88
    4.18 0.41 0.79 1.98
    5.66 0.29 0.88 2.35
U-NGAL 0 h 0.8495 <0.0001 0.48 0.90 0.72 3.23
    1.20 0.67 0.80 3.33
    1.47 0.62 0.84 3.87
    3.04 0.52 0.88 4.37
    3.87 0.52 0.92 6.55
    5.01 0.48 0.96 11.9
U-NGAL 2 h 0.7525 0.00644 0.47 0.82 0.54 1.8
    0.80 0.65 0.71 2.22
    2.35 0.59 0.75 2.35
    2.49 0.53 0.79 2.54
    3.67 0.47 0.83 2.82
    5.32 0.41 0.83 2.47
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Figure 6. (A & B) Urinary apoM (nmol/l) (A) and urinary NGAL (nmol/l) (B) at baseline (n = 20) and 2 h 
postoperatively (n = 17) in children with AKI after cardiac surgery and in adult patients with nondiabetic 
glomerulonephritis and proteinuria (n = 8). Bars represent medians. (C) Urinary apoA1 (nmol/l) at 2 h 
postoperatively in children without (n = 25) and with AKI (n = 17) after cardiac surgery and in adult patients with 
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can be the attributable factor to the lack of differ-
ence at 0 h. The relatively low AUC value and lack 
of dose-effect relationship of U-apoM in the whole 
cohort is possibly a reflection of the confounding 
hematuria. The ELISA employed cannot distinguish 
between apoM derived from the kidney and plasma. 
Therefore, U-apoM as a predictive biomarker of AKI 
is most likely not a suitable biomarker in the present 
clinical setting.
The biochemical characterization supports that 
U-apoM is derived from the kidney rather than plasma 
HDL. In plasma, apoM is tightly associated with large 
lipoproteins (>160 kDa). In urine, apoM co-eluted 
with small (14–44 kDa) proteins, indicating no lipo-
protein association. U-apoM was absent in patients 
with severe proteinuria, suggesting that the HDL-asso-
ciated plasma apoM is not filtered into the urine to a 
significant extent, even when the glomerular barrier is 
defect. Moreover, the relative concentration of apoA1 
in urine compared with plasma was much lower than 
that of apoM. This further implies that the increase 
in U-apoM in children after heart surgery is not due 
to loss of plasma HDL to the urine, since there is no 
concurrent increase in U-apoA1, which is a surrogate 
marker of HDL. The idea that U-apoM is derived 
from the kidney is consistent with our previous obser-
vation in mice, that is, that U-apoM secretion in mice 
with a defective megalin receptor mediated uptake of 
apoM in the proximal tubules results in loss of kidney-
derived apoM [12].
Elevated levels of U-NGAL have been reported in 
proteinuric patients with positive correlation to the 
severity of proteinuria [43]. The low U-NGAL level of 
the proteinuric patients in the present study compared 
with a report by Bolignano et al. [44] might partly be 
due to approximately four-times lower levels of pro-
teinuria. However, the presence of different types of 
glomerular disease and angiotensin receptor blockade 
at maximum dose in our proteinuric patients are possi-
bly contributing causes to the lower levels of U-NGAL.
The reason why apoM under normal conditions 
likely undergoes secretion and reabsorption in the 
kidney is yet to be found. Plasma apoM is a carrier of 
S1P which is a bioactive lipid. Notably, S1P has vaso-
protective effects and prevents AKI in an ischemia-
reperfusion mouse model [45,46]. Four S1P receptors 
(S1P
1–4





 being upregulated after ischemia-reperfusion 
injury [45]. Hence, apoM could work as a kidney-pro-
tective co-factor for delivery of S1P to the tubular epi-
thelium.
Limitations of the present study include that it is a 
small population, single-center analysis. Furthermore 
we only investigated patients in one specific clinical set-
ting, which does not reflect the multifactorial etiology 
of AKI. As already discussed, possible blood contami-
nation of urine makes U-apoM measurements hard to 
interprete, since our current ELISA cannot distinguish 
between apoM derived from plasma and apoM from 
the proximal tubules reflecting AKI. Finally, a great 
disadvantage of urinary diagnostics is the scarcity of 
urine in oliguric patients which can make it difficult 
to obtain the required amount of urine necessary for 
analysis.
Conclusion
ApoM, which is normally essentially absent in urine, is 
secreted into the urine of children after cardiac surgery. 
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Figure 7. Gel-filtration chromatography on urine collected 2 h after ended heart surgery from patients who developed acute 
kidney injury (AKI). (A) A pool of urine from five patients (400 μl) concentrated sevenfold and sterile filtered was loaded on to a 
Superose 6 10/300 GL fast protein liquid column. Fractions (∼280 μl) were collected, and protein content and elution profile was 
determined by absorbance at 280 nm. Elution volumes for plasma lipoproteins are shown. From each of five adjacent fractions, 50 
μl were pooled to a total of 250 μl and concentrated to 15 μl before electrophoresis in 12% polyacrylamide gels under denaturing 
and reducing conditions. Subsequently, western blotting was done against apoM (rabbit polyclonal antihuman apoM, EPR2904) 
followed by stripping and reincubation with anti-apoA1 antibodies. (B) Urine from one patient was run on Superose 6 and 12 in 
serial connection following the same procedure as in (A). 100 μl from each of seven adjacent fractions were pooled and concentrated 
23–28-fold before western blotting against apoM (rabbit polyclonal antihuman apoM). Single fractions within the pools where apoM 
eluted were concentrated fivefold before repeating the apoM western blot with a monoclonal antihuman apoM antibody (M58). 
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The U-apoM concentration was highest in the children 
who developed AKI, implying that the degree of kid-
ney affection during surgery determines apoM secre-
tion. U-apoM and U-NGAL are highly correlated. 
U-NGAL is better in predicting AKI than U-apoM 
and U-apoM does not substantially add to the diag-
nostic power of U-NGAL. ApoM is not secreted in the 
urine of severely proteinuric patients, which supports 
the possibility that U-apoM could be a specific marker 
of damage to the proximal tubules. However, in the 
present clinical setting, apoM is likely not a suitable 
biomarker of AKI, as reflected in the relatively low 
AUC.
Future perspective
The present study has added U-apoM to the list of 
early biomarkers of AKI. Measurements of U-apoM in 
future studies will cast light upon the diagnostic value 
of apoM in different AKI patient cohorts. With the 
recent discovery that apoM carries S1P, which medi-
ates endothelial barrier protective functions, it would 
be of interest to determine whether human apoM has 
renoprotective effects during AKI.
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